Shahid Beheshti University of Medical Sciences
  • Register
  • Login

Journal of Lasers in Medical Sciences

  • Home
  • Issues
    • Current Issue
    • Archives
  • Journal Info
    • About the Journal
    • Editorial Team
    • Indexing/Abstracting
    • Contact Us
  • Author Guideline
    • Submission Guide
    • Author Statement Form
    • Peer Review Process
    • Publication Fee
  • Ethics & Policies
    • Ethical Requirements
    • Archiving
    • Authorship Rules
    • Withdrawal Regulations
    • Retraction Considerations
    • Privacy Statement
    • Licensing
    • Copyright Terms
  • Reviewer Guideline
  • New Submission
Advanced Search
  1. Home
  2. Archives
  3. Vol. 16 (2025): Continues Volume
  4. Original Article

Vol. 16 (2025)

Bahman 2025

Evaluation of Verteporfin as a Photosensitizer With Anticancer Activity Via System Biology Tools Evaluation of verteporfin as a photosensitizer with anticancer activity

  • Alireza Ahmadzadeh
  • Babak Arjmand
  • Zahra Razzaghi
  • Fatemeh Bandarian
  • Mitra Rezaei

Journal of Lasers in Medical Sciences, Vol. 16 (2025), 21 Bahman 2025 , Page e25
Published: 2025-08-18

  • View Article
  • Download
  • Cite
  • References
  • Statastics
  • Share

Abstract

Introduction: Verteporfin as a photosensitizer in photodynamic therapy (PDT) is used to inhibit deviant choroidal vascularization. This agent also has an anticancer property. The effective treatment of various tumors such as melanoma by using verteporfin is confirmed. In the present study, the ability of verteporfin in growth inhibition of MKN45 is investigated via protein-protein interaction (PPI) analysis to explore its beneficial role in PDT.

Methods: The gene expression profiles of the treated MKN45 cell with verteporfin are mined from the Gene Expression Omnibus (GEO) database and evaluated via PPI network analysis to find the central genes. The central genes are searched in the GeneCards database to find the more related genes to gastric cancer. The expression amounts of the top central genes related to stomach adenocarcinoma are extracted from the University of Alabama at Birmingham Cancer data analysis Portal (UALCAN).

Results: Among 2356 significant differentially expressed genes (DEGs), 58 hub-bottlenecks were determined via PPI network analysis. ERBB2, EGFR, CREBBP, CTSD, PSEN1, HRAS, PIK3R1, NRAS, NFKBIA, FOS, CTSB, CALR, NFE2L2, RHOA, CDKN1A, ITGB1, APP, CD44, HSPA5, and HMGCR were pointed out as the crucial genes. The expression amounts of ERBB2, EGFR, CREBBP, CTSD, and PSEN1 genes which were highlighted as critical genes via the directed PPI network were explored for stomach adenocarcinoma.

Conclusion: In conclusion, the anticancer property of verteporfin was highlighted. This finding
can improve the efficacy of related PDT.

Keywords:
  • Verteporfin, Photosensitizer, Anticancer, Gene expression, Network analysis
  • PDF

How to Cite

Ahmadzadeh, A., Arjmand, B., Razzaghi, Z., Bandarian, F., & Rezaei, M. (2025). Evaluation of Verteporfin as a Photosensitizer With Anticancer Activity Via System Biology Tools: Evaluation of verteporfin as a photosensitizer with anticancer activity. Journal of Lasers in Medical Sciences, 16, e25. Retrieved from https://journals.sbmu.ac.ir/jlms/article/view/47672
  • ACM
  • ACS
  • APA
  • ABNT
  • Chicago
  • Harvard
  • IEEE
  • MLA
  • Turabian
  • Vancouver
  • Endnote/Zotero/Mendeley (RIS)
  • BibTeX

References

Please see the references list in the PDF file.

  • Abstract Viewed: 358 times
  • PDF Downloaded: 359 times

Download Statastics

  • Linkedin
  • Twitter
  • Facebook
  • Google Plus
  • Telegram

Make a Submission

Make a Submission

Information

  • For Readers
  • For Authors
  • For Librarians

Developed By

Open Journal Systems
  • Home
  • Archives
  • Submissions
  • About the Journal
  • Editorial Team
  • Contact

Iranian Medical Laser Association 

                                        

 

This journal is distributed under the terms of CC BY-NC 4.0.
Design and publishing by SBMU journals. All credits and honors to PKP for their OJS. 

Powered by OJSPlus